- AbbVie Presents New Data for VENCLEXTA/VENCLYXTO in 1L CLL Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
- Ascentage Pharma Presents Multiple Clinical Updates of olverembatinib and lisaftoclax
- BeOne Showcases Landmark Ph 3 Data in CLL Patients Aged 80+ Reinforcing BRUKINSA Benefit
- BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation
- BioInvent’s BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC
- CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B
- Cellectis Presents Final Ph 1 Results of Lasme-cel and Preliminary Results on Eti-cel
- Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with 1L DLBCL
- Enterome presents Ph 1/2 iNHL interim data demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity
- Enliven Therapeutics Announces Oral Presentation Featuring Additional Positive Ph 1 Clinical Trial Data for ELVN-001 in CML
- Faron Presents Matured BEXMAB Data Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS
- Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab + R2 in R/R FL Patients
- Halia Therapeutics Presents Final Ph 2 Ofirnoflast Data in Lower-Risk MDS
- Imviva Biotech Presents Studies on CTD402 Allogeneic CAR-T Therapy
- Incyte Announces New Positive Data Showing INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
- Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
- Legend Biotech Establishes Clinical Proof-of-Concept for LB2501 in R/R B-Cell NHL
- Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with LBCL
- Mabwell Presents Latest Clinical Results of Novel Anti-TMPRSS6 Monoclonal Antibody 9MW3011
- Menarini Group Reports Data from Ph 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis
- New TALVEY (talquetamab) + daratumumab data in earlier-line R/R multiple myeloma presented
- ORYZON Presents Updated Positive Clinical Data for Iadademstat in AML
- Results from Incyte’s Pivotal Ph 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Showed Prolonged PFS
- Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
- Syndax Pharmaceuticals announced data from Ph 1/2 SAVE trial of an all-oral regimen of Revuforj® (revumenib), decitabine/cedazuridine, and venetoclax in R/R NPM1m, KMT2Ar, or NUP98r AML